Value proposition

DARC, a retinal biomarker with AI, advancing drug development for AMD & glaucoma therapeutics

Early Detection Prevents Blindness and Disability:
Novai is on a mission to combat blindness and disability by pioneering early detection and intervention for eye and brain diseases. At the heart of Novai's innovation is the DARC technology (Detection of Apoptosing Retinal Cells), a novel combination of a proprietary biologic and Artificial Intelligence (AI).

The Eye is a Window on to the Brain:
DARC stands alone as the sole technology with the ability to observe single cell stress and programmed cell death in the retina. This breakthrough positions DARC as the go-to biomarker to inform clinical decision-making in both ophthalmic and neurodegenerative diseases such as macular degeneration, glaucoma, diabetes, Parkinson's, multiple sclerosis and Alzheimer's.

Expertise, Experience and Traction:
The company boasts an expert and experienced leadership and advisory team, strong IP rights, and a clear strategy targeting a $40 billion market. Novai has generated £4.2 million from signed sales contracts, contributing to drug development and risk mitigation for Pharma companies using DARC.

Series A for Mainstream Adoption:
With £4.5 million in investments and £3.3 million in non-dilutive funding secured, Novai is currently on a fundraising drive to raise an additional £10 million towards approval of its use in clinic.

DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA.

Novai is headquartered in Reading, UK. For more information, please visit our website www.novai.co.uk

Biotechnology, Drug Development, Pharmaceutical, Opthalmology, Artificial Intelligence, Glaucoma, Age-related Macular Degeneration, Retinal, Neurodegeneration, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Biomarker